论文部分内容阅读
目的探讨培菲康联合三联疗法根除幽门螺杆菌(Helicobacter pylori,Hp)的临床疗效。方法选择宁波市北仑区人民医院收治的84例幽门螺杆菌感染患者作为观察对象,随机分为治疗组(n=42)和对照组(n=42),对照组采用标准三联(即奥美拉唑、阿莫西林、克拉霉素)口服;治疗组在对照组基础上加培菲康口服。比较2组治疗后Hp成功根除率,消化道症状缓解情况和不良反应发生率。结果治疗组Hp根除率为92.9%,高于对照组75.0%,差具有统计学意义(P<0.05);治疗组不良反应发生率为2.4%,明显低于对照组10.0%,差异具有统计学意义(P<0.05);治疗组症状缓解总有效率为90.5%,明显高于对照组75.0%,差具有统计学意义(P<0.05)。结论培菲康联合三联疗法对于幽门螺杆菌根除率高,效果显著,并能有效的减少胃肠道不良反应。
Objective To investigate the clinical efficacy of combination of pefloxacin with triple therapy in the treatment of Helicobacter pylori (Hp). Methods Eighty-four patients with Helicobacter pylori infection who were treated in Beilun District People’s Hospital of Ningbo were selected and randomly divided into treatment group (n = 42) and control group (n = 42). The control group was treated with standard triple therapy Azole, amoxicillin, clarithromycin); the treatment group was given Peifeikang orally on the basis of the control group. The successful eradication rate of Hp, the relief of gastrointestinal symptoms and the incidence of adverse reactions were compared between the two groups. Results The eradication rate of Hp in the treatment group was 92.9%, which was significantly higher than that in the control group (75.0%) (P <0.05). The incidence of adverse reactions in the treatment group was 2.4%, which was significantly lower than that in the control group (10.0% (P <0.05). The total effective rate of the treatment group was 90.5%, which was significantly higher than that of the control group (75.0%), the difference was statistically significant (P <0.05). Conclusion Pefikang combined triple therapy for Helicobacter pylori eradication rate is high, the effect is significant, and can effectively reduce gastrointestinal adverse reactions.